Cardiosolutions

Cardiosolutions, Inc. operates as a development-stage medical device company, focusing on a less invasive, percutaneous alternative to open-heart surgery for mitral valve repair. The company was established in 2006 and originated as a novel medical device technology incubated within and spun out of Primo Medical Group Inc. Key strategic partners and investors include BioVentures Investors and LivaNova (formerly Sorin Group). In 2012, Cardiosolutions secured a significant minority investment of $8 million from the Sorin Group, which was intended to finance ongoing product development and clinical testing, with Sorin also holding an option to acquire the company in the future. The total funding raised by the company over four rounds amounted to $22.3 million.

The core of Cardiosolutions' work is the development of a system to treat patients with moderate to severe mitral and/or tricuspid valve regurgitation. This condition affects a significant portion of the global population, with many patients being unsuitable for traditional surgery. The company's main product under development was the Mitra-Spacer™, an implant delivered via a proprietary catheter system, the Percu-Pro™ System. The Mitra-Spacer is designed to fill the void created by a dilated annulus or a deteriorating valve, providing a sealing surface for the valve leaflets to reduce regurgitation. This technology aimed to offer a long-term therapeutic solution for patients who are not candidates for surgery or are seeking a less invasive option. In 2017, the company received a Notice of Allowance from the U.S. Patent and Trademark Office for its 'spacer' technology, covering critical functions for percutaneous delivery and anchoring of the implant.

In June 2012, Cardiosolutions received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Dexterity™ Steerable Introducer. This device is designed to simplify trans-septal cardiac procedures by providing straightforward access to the heart's anatomy, facilitating the delivery of various cardiovascular catheters. The company is based in West Bridgewater, Massachusetts. According to market intelligence platforms, Cardiosolutions is now considered a 'deadpooled' or 'out of business' company as of October 2021.

Keywords: percutaneous valve repair, mitral regurgitation, tricuspid valve regurgitation, Mitra-Spacer, coaptation device, heart valve repair, medical device, structural heart, catheter delivery system, spacer technology, valvular heart disease, Dexterity Steerable Introducer, Primo Medical Group, BioVentures Investors, Sorin Group, LivaNova, cardiovascular device, heart failure treatment